Pharming Group NL0010391025

Vierde Tranche: 20 mei?

1. [verwijderd] 17 mei 2013 12:41

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Aandeelhouders Pharming steunen reverse split
   Pharming wil converteerbare lening uitgeven
   
   LEIDEN (AFN) - Biotechnologiebedrijf Pharming heeft de derde tranche van een eerder aangekondigde converteerbare obligatielening uitgegeven. Dat heeft Pharming dinsdag gemeld.
   
   Obligatiehouders kregen daarbij in totaal 26,6 miljoen aandelen uitgekeerd als een vooruitbetaling voor de aflossing en rentebetaling die op 20 mei plaats zal vinden. Het totaal aantal aandelen Pharming is toegenomen tot bijna 169 miljoen.
   
   Pharming kondigde in januari aan een obligatielening ter waarde van 16,35 miljoen euro uit te geven. Dat gebeurt in maandelijkse termijnen tot oktober van dit jaar. Het geld dat Pharming met de lening ophaalt, wil het bedrijf gebruiken om de balans te versterken en te zorgen voor voldoende werkkapitaal in afwachting van de Amerikaanse goedkeuring van het medicijn Ruconest.
2. voda 21 mei 2013 18:04

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 09 mei 2024

   • Aanbevelingen

     Ontvangen: 82706

     Gegeven: 20988

   •    Aantal posts: 365.568

   21 mei dus:
   
   Pharming Confirms Completion Of Redemption Of Third Tranche And The Redemption Of Fourth Tranche Of Convertible Bond
   
   Leiden, The Netherlands, May 21, 2013. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that it completed the redemption of the third tranche and redeemed the fourth tranche of its €16.35 million convertible bond.
   
   A total of 7,482,994 shares were issued to the bondholders to serve the balance between the 26,605,121 shares that were issued on 16 April, as pre-installment for the May 20, 2013 redemption and interest payment, and the total number of shares due to complete the redemption of the third tranche under the terms and conditions of the bond.
   
   In addition 32,787,213 shares were issued to the bondholders, serving as a pre-installment for the June 21, 2013 redemption of the fourth tranche and interest payment, under the terms and conditions of the bond.
   
   About the January 2013 Convertible Bonds
   As announced in our press release on January 16, 2013, and following the approval of the increase of the Company’s authorized share capital during the extraordinary general meeting of shareholders, which was held on February 28, 2013, Pharming will redeem the bond on a month by month basis in seven equal tranches, of which four have now been redeemed, such that redemption of the bond will be completed on October 01, 2013. Remaining redemption dates after 21 June are; 25 July, 28 August and 01 October.
   As of today, the number of outstanding shares has increased from 168,909,635 to 209,179,842.
   
   About Pharming Group NV
   Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST is partnered with Santarus Inc (NASDAQ: SNTS) in North America where a BLA for RUCONEST was submitted to the FDA in April 2013. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that, with the EU approval of Pharming’s rhC1 inhibitor, has proven capable of producing industrial volumes of high quality recombinant human protein in a significantly more economical way through low upfront capital investment and manufacturing costs, compared to current cell based technologies. Pharming now plans to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A.
   
   This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
   
3. 311 22 mei 2013 01:06

   auteur info

   • 311

     Lid sinds: 15 dec 2012

     Laatste bezoek: 13 jul 2022

   • Aanbevelingen

     Ontvangen: 28

     Gegeven: 677

   •    Aantal posts: 165

   ...Tov voor dit financieringsmechanisme is het aantal uitstaande aandelen al met 75 % (!) uitgebreid en is de koers met een zelfde percentage gezakt...
4. [verwijderd] 21 juni 2013 17:00

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   we inademen tot 25 juli !!!!
   
   Leiden, The Netherlands, 21 June 2013. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that it has completed the redemption of the fourth tranche of its €16.35 million convertible bond. As result of the increase of the share price over the last month, no additional shares needed to be issued to the bondholders to serve the balance between the shares that were issued, as announced on 21 May, as pre-installment for the 21 June redemption and interest payment, under the terms and conditions of the bond.
   
   About the January 2013 Convertible Bonds
   As announced in our press release on 16 January 2013, and following the approval of the increase of the Company’s authorized share capital during the extraordinary general meeting of shareholders, which was held on 28 February 2013, Pharming will redeem the bond on a month by month basis in seven equal tranches, of which four have now been redeemed, such that redemption of the bond will be completed on 1 October 2013. Remaining redemption dates are; 25 July, 28 August and 1 October.